A<scp>d</scp>‐optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients

Abstract

The optimal design performed well and the pharmacokinetics of itraconazole and hydroxy-itraconazole were described adequately by the model. The relative bioavailability for itraconazole capsules was 82% compared with the solution.